Zimmer Holdings Price Target Raised to $108.00 at BMO Capital Markets (ZMH)
Analysts at BMO Capital Markets raised their price objective on shares of Zimmer Holdings (NYSE:ZMH) from $100.00 to $108.00 in a research report issued to clients and investors on Friday, AmericanBankingNews.com reports. BMO Capital Markets’ target price suggests a potential upside of 16.08% from the company’s current price.
ZMH has been the subject of a number of other recent research reports. Analysts at Deutsche Bank raised their price target on shares of Zimmer Holdings from $98.00 to $100.00 in a research note to investors on Friday. Separately, analysts at Cowen and Company raised their price target on shares of Zimmer Holdings from $84.00 to $96.00 in a research note to investors on Friday. Finally, analysts at Brean Capital raised their price target on shares of Zimmer Holdings from $90.00 to $111.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Two analysts have rated the stock with a sell rating, six have given a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $93.48.
Shares of Zimmer Holdings (NYSE:ZMH) traded up 0.19% on Friday, hitting $93.22. 210,928 shares of the company’s stock traded hands. Zimmer Holdings has a 1-year low of $72.24 and a 1-year high of $97.86. The stock’s 50-day moving average is $93.9 and its 200-day moving average is $87.08. The company has a market cap of $15.939 billion and a P/E ratio of 23.58.
Zimmer Holdings (NYSE:ZMH) last issued its quarterly earnings data on Friday, January 31st. The company reported $1.36 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.62 by $0.26. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.22 billion. On average, analysts predict that Zimmer Holdings will post $5.71 earnings per share for the current fiscal year.
Zimmer Holdings, Inc (NYSE:ZMH) designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, biologics, dental implants and related surgical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.